Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO

Watchlist Manager
Crescent Biopharma Inc (Pre-Reincorporation) Logo
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Watchlist
Price: 11.85 USD -3.03% Market Closed
Market Cap: 164.6m USD

Intrinsic Value

The intrinsic value of one CBIO stock under the Base Case scenario is 28.31 USD. Compared to the current market price of 11.85 USD, Crescent Biopharma Inc (Pre-Reincorporation) is Undervalued by 58%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CBIO Intrinsic Value
28.31 USD
Undervaluation 58%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Crescent Biopharma Inc (Pre-Reincorporation)

What is Valuation History?
Ask AI Assistant
What other research platforms think about CBIO?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CBIO valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Crescent Biopharma Inc (Pre-Reincorporation).

Explain Valuation
Compare CBIO to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CBIO?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Crescent Biopharma Inc (Pre-Reincorporation)

Current Assets 11.1m
Cash & Short-Term Investments 10.7m
Receivables 136.6k
Other Current Assets 234.7k
Current Liabilities 5.8m
Accounts Payable 329.3k
Accrued Liabilities 5.4m
Efficiency

Free Cash Flow Analysis
Crescent Biopharma Inc (Pre-Reincorporation)

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Crescent Biopharma Inc (Pre-Reincorporation)

Revenue
0 USD
Operating Expenses
-32.5m USD
Operating Income
-32.5m USD
Other Expenses
-5.4m USD
Net Income
-37.9m USD
Fundamental Scores

CBIO Profitability Score
Profitability Due Diligence

Crescent Biopharma Inc (Pre-Reincorporation)'s profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Negative 3Y Average Net Margin
Negative 3Y Average Operating Margin
Declining ROE
18/100
Profitability
Score

Crescent Biopharma Inc (Pre-Reincorporation)'s profitability score is 18/100. The higher the profitability score, the more profitable the company is.

CBIO Solvency Score
Solvency Due Diligence

Crescent Biopharma Inc (Pre-Reincorporation)'s solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Crescent Biopharma Inc (Pre-Reincorporation)'s solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CBIO Price Targets Summary
Crescent Biopharma Inc (Pre-Reincorporation)

Wall Street analysts forecast CBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CBIO is 27.03 USD with a low forecast of 22.22 USD and a high forecast of 33.6 USD.

Lowest
Price Target
22.22 USD
88% Upside
Average
Price Target
27.03 USD
128% Upside
Highest
Price Target
33.6 USD
184% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for CBIO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

CBIO Insider Trading
Buy and sell transactions by insiders

CBIO News

What is the Intrinsic Value of one CBIO stock?

The intrinsic value of one CBIO stock under the Base Case scenario is 28.31 USD.

Is CBIO stock undervalued or overvalued?

Compared to the current market price of 11.85 USD, Crescent Biopharma Inc (Pre-Reincorporation) is Undervalued by 58%.

Back to Top